Recurrent abnormalities of the short arm of chromosome 9, including translocations and interstitial deletions, have been reported in both leukemia and lymphoma. The pathologic consequences of these abnormalities remain unknown. The cyclin-dependent kinase 4 inhibitor (CDKN2j gene. which maps to 9p21, has been implicated by the finding of a high frequency of biallelic deletions in leukemic cell lines. We have determined the incidence of structural abnormalities affecting CDKN2 by DNA blot in a panel of 231 cases of leukemia and lymphoma and 66 cell lines derived from patients with lymphoid malignancies with defined cytogenetic abnormalities. Structural alterations of CDKN2 were seen in 20 (8.39'0) of all fresh cases and 10 (15.146) of all cell lines.
Recurrent abnormalities of the short arm of chromosome 9, including translocations and interstitial deletions, have been reported in both leukemia and lymphoma. The pathologic consequences of these abnormalities remain unknown. The cyclin-dependent kinase 4 inhibitor (CDKN2j gene. which maps to 9p21, has been implicated by the finding of a high frequency of biallelic deletions in leukemic cell lines. We have determined the incidence of structural abnormalities affecting CDKN2 by DNA blot in a panel of 231 cases of leukemia and lymphoma and 66 cell lines derived from patients with lymphoid malignancies with defined cytogenetic abnormalities. Structural alterations of CDKN2 were seen in 20 (8. 39 '0) of all fresh cases and 10 (15.146) of all cell lines.
Biallelic CMN2 deletions were seen in 11 of 53 (21%) cases of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). There was no association with any particular cytogenetic abnormalii. Biallelic deletions were also found in highgrade and transformed non-Hodgkin's lymphoma (NHL) of both B-and T-cell lineages. In two cases of transformed NHL, analysis of sequential samples showed loss of CDKN2 with transformation. Neither deletions nor rearrangements of the CDKN2 gene were seen in any of the 119 leukemias of mature B or T cells analyzed. Biallelic deletions of CDKN2 were ECURRENT ABNORMALITIES of a localized region of the short arm of chromosome 9 (9p13-p22) have been reported in a wide variety of tumors including melanomas,' gliomas,' non-small cell lung carcinoma~,~ and bladder tumors: as well as and lymphomas.' Recent improvements in the genetic map of this region, combined with loss of heterozygosity studies and deletion mapping, have indicated the presence of at least one and possibly two8s9 tumor-suppressor genes on 9p.
In hematologic malignancies in which high-resolution cytogenetics are often possible, a variety of recurrent abnormalities of 9p, including interstitial deletions and translocations, have been observed. These abnormalities may correlate with histologic and clinical subsets of disease. In acute leukemias, one of the most common abnormalities is interstitial deletion of 9p21-22, seen in 7% to 12% of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL).''." In the lymphomas and chronic leukemias, translocations involving 9p13, eg, t(9; 14)(p13;q32),I2 have been reported in lymphoplasmacytoid non-Hodgkin's lymphoma (NHL), an indolent B-cell lymphoma, although weI3 and others14.15 have observed translocation t(8;9)(q24.l;p13.3) in high-grade Bcell malignancies.
The nature of the crucial genes involved in the deletions of BCP-ALL, as well as the translocations of B-NHL, remain unknown. Although one t(9; 14)(p13;q32) translocation breakpoint has been cloned from a B-NHL cell line,'6 the derived probes do not detect breakpoints in other cases and in our hands do not detect transcripts (G.S. and M.J.S.D., unpublished observations). Similarly, another possible candidate gene, PAX& a B-cell transcription factor that has also been mapped to 9~1 3 , " does not appear to be involved in observed in 6 of 13 NHL cell lines. Three of the 6 cases had undergone transformation from low-to high-grade disease: in 2 of these cases it was possible to show that the CDKN2 deletions were present in fresh material from the patient and were therefore not an artifact of in vitro culture. Rearrangements of CDKN2 were seen in 2 cases (4%) of BCP-ALL, in 1 case of B-NHL, and in 1 Burkws lymphoma cell line and suggest the presence of a "hot spot" for recombination in the vicinity of the CDKN2 gene. These data indicate that the loss of CDKN2 expression may be involved in the pathogenesis of a subset of BCP-ALL, some high-grade NHL, and in the transformation of NHL from low-to high-grade disease. CDKN2 deletions and rearrangements occurred in the absence of detectable cytogenetic changes of chromosome 9p in 25 of 30 ( 8 3 % ) cases. Finally, of 10 cases of BCP-ALL that produced overt, transplantable leukemia in mice with severe combined immunodeficiency (SCID), seven showed biallelic CDKN2 deletions. In contrast, none of 11 cases that failed to engraft showed biallelic CDKN2 deletions. BCP-ALL cases that lack CDKN2 expression may have a particular propensity to grow in SCID mice. Recently, a gene involved in the control of the cell cycle has been mapped to chromosome 9p21. This gene, the cyclin-dependent kinase 4 inhibitor (also known as MTSl or p16, but now renamed CDKN2) prevents progression through the cell cycle when complexed with cdk4.I' Biallelic deletions of CDKN2 have been detected at high frequency in many malignant cell lines, including leukemic cell line^.'^.'^ CDKN2 has therefore been postulated to act as a tumorsuppressor gene, the loss of which is associated with loss of control of the cell cycle. However, preliminary studies in primary bladder tumors have shown that CDKN2 deletions occur at a much lower frequency in primary tumors than in cell lines." This raised the possibility that the high frequency of deletions observed in cell lines may represent an artifact of in vitro culture.
We have determined the incidence of CDKN2 abnormalities by DNA blot in a range of both fresh cases and cell lines derived from patients with lymphoid malignancies with defined cytogenetic abnormalities. The data indicate that not only biallelic deletions but also rearrangements of CDKN2 occur both in a subset of BCP-ALL and high-grade NHL and may be involved in the process of transformation of low-grade NHL to more aggressive diseases. Furthermore, cases of both BCP-ALL and NHL with biallelic CDKN2 deletions may have increased ability to proliferate when transplanted into mice with severe combined immunodeficiency (SCID).
MATERIALS AND METHODS
Patient population. Diagnosis was made on the basis of combined morphologic, immunophenotypic, cytogenetic, and genotypic analyses, using previously defined riter ria.^^.^^ High molecular weight DNA was isolated from a mononuclear fraction of peripheral blood, bone marrow, hiopsied lymph node, or splenectomy specimens after informed patient consent was obtained. DNA blot analysis. Structural abnormalities of CDKN2 were sought by DNA blot because residual contaminating normal cells may confound analysis by polymerase chain reaction (PCR). DNA blot was performed as previously described." The CDKN2 probe was a 330-bp fragment containing the exon one of the CDKN2 gene; this probe was obtained by PCR amplification from normal human genomic DNA using described primers." This probe contains the 
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6. All DNA samples were digested with at least BarnHI and EcoRI. BamHI produces an approximately 25-kb germline fragment that spans the entire CDKN2 gene and therefore the combination of this enzyme and the exon 1 probe will detect all rearrangements and large deletions within the CDKN2 gene. All filters had been previously probed with Ig, T-cell receptor (TCR), and various oncogene probes that allowed an estimation of contaminating normal cells to be made. SCID mice. SCID mice were obtained from The National Institute of Medical Research (Mill Hill, London, UK). They were maintained in a specific pathogen-free environment and were irradiated with 200 cGy and injected intravenously with 2 X lo7 leukemic cells from patients with BCP-ALL by tail vein injection. Assessment of engraftment and transplantation of human leukemic cells was performed as described?' DNA was extracted from spleens with leukemic infiltration containing greater than 95% leukemic cells as assessed by flow cytometry.
7.
RESULTS
A total of 231 cases of lymphoid leukemia or lymphoma and 66 cell lines representing malignancies of both B-, and T-cell lineages at various stages of differentiation were analyzed. Overall, biallelic deletions of CDKNZ were observed in 17 (7.3%) and rearrangements of CDKNZ in 3 (1.3%) fresh cases. Of the lymphoid cell lines, 9 (13.6%) exhibited biallelic deletion and 1 (l .5%) exhibited rearrangement. Results are summarised in Tables 1 and 2 and are discussed according to the diagnostic subgroups below.
For personal use only. on December 27, 2017. by guest www.bloodjournal.org From ALL. Fifty-three cases of BCP-ALL were examined and, of these, 11 cases exhibited biallelic deletions of CDKN2 (Figs 2 and 3) . Cases with biallelic deletions comprised a heterogeneous clinical group and were not associated with any consistent cytogenetic abnormality, as shown in Table  3 . In particular, of the 17 cases of BCP-ALL with the t(9;22)(q34;qll), only 4 exhibited CDKN2 deletions; 2 of these cases had cytogenetically detectable rearrangements of chromosome 9p (cases no. 6 and 11, Table 3 ). Two of the four cases with t(9;22)(q34;qll) were BCP-ALL arising as blast crisis of chronic myeloid leukemia (cases no. 6 and 10, Table 3 ); whether loss of CDKN2 was associated with this transformation could not be determined because of the lack of suitable specimens. One patient with t(4; 1 l)(q21;q23) retained germline CDKN2. Of the two BCP-ALL lines examined, one (UoCB1) showed biallelic CDKN2 deletion, whereas UoCB4 retained germline configuration. The availability of these cell lines permitted high-resolution cytogenetics, but no structural abnormalities of the short arm of chromosome 9p were detected. These data therefore confirm that CDKN2 deletions for the most part occurred in the absence of the interstitial deletion 9p21-22.
Two cases (3.8% of the total) exhibited CDkW2 rearrangements (cases no. 13 and 14, Table 3 and Fig 3) . These cases again lacked cytogenetic change at chromosome 9p. Rearrangements were seen in multiple restriction enzyme digests, were not seen in normal cases, and were therefore neither simple polymorphisms nor point mutations. In case no. 13, the rearranged allele was associated with deletion of the other allele, whereas, in case no. 14, both alleles of CDKN2 were rearranged (Fig 3) . In both of these cases and in all other cases with CDKN2 rearrangements (see below), a germline configuration was observed in EcoFU digests with the CDKN2 exon I probe. Molecular cloning experiments in case no. 14 are being undertaken to define further the nature of these rearrangements. Finally, leukemic blasts from some cases of BCP-ALL have been shown to produce overt, transplantable disease when inoculated into SCID mice.*' We have established 11 such transplantable cell lines from a total of 27 different BCP-ALL samples. Some of these lines have been shown to maintain identical ZGH rearrangements to those observed in patient material over several passages (J.M. Heward, M.J.S.D., and P.M., unpublished observations, 1994). Seven of 10 BCP-ALL lines that grow in SCID mice and the original patient material showed biallelic CDKN2 deletions (Ta- Table 3 . Note 3 CDKNZ hybridizing fragments of differing intensity in Daudi in both BsmHl and Pst I digests. Note also biallelic CDKNZ deletions in patient no. 6 . Cross-hybridizing bands of varying intensity were seen with the CDKNZexon 1 probe despite stringent washing in 0.1 x SSC 0.1% sodium dodecyl sulfate; the significance of these bands is unknown. Note that there is little homology between the 5' regions of CDKNZ and the related p15 gene that is also located at 9~21.2' ble 3). In contrast, 10 of the 1 1 cases analyzed that failed to grow in SCID mice retained germline CDKN2, whereas case no. 14, which showed biallelic CDKN2 rearrangement, also failed to grow. The differences between these groups are statistically significant (P = .001, Fisher's exact test).
Three cases of BCP-ALL with germline CDKN2 did grow in SCID mice; details of these cases are given in Table 3 as cases no. 15 through 17. Case no. 15 exhibited a t(9; 15)(p21;q15) translocation, but no rearrangement of CDKN2 on DNA blot (Fig 2) . None of the 1 I cases of TCP-ALL showed deletion or rearrangement of CDKN2.
Burkitt's lymphoma. A panel of 8 sporadic cases of Burkitt's lymphoma and 26 cell lines derived from both sporadic and endemic cases was examined. One of the eight fresh cases and 1 of 26 cell lines exhibited biallelic CDKN2 deletions. One of the Burkitt's cell lines (Daudi) exhibited three apparently rearranged fragments of differing intensity in multiple enzyme digests, without any loss of the germline signal (Fig 2) . All EBV-transformed normal B-cell lines derived from patients with Burkitt's lymphoma failed to show any CDKN2 abnormality (Fig 4) .
De novo B-cell leukemias with t(14; 18)(q32.3;q21.3). An aggressive subset of B-cell leukemia has been recognized; these leukemias have concurrent activation of BCL2 and MYC oncogenes. Three cell lines (Karpas 231, Karpas 353,13 and KMH-2B2') and three fresh cases were analyzed. Karpas 231 was derived from one of the fresh cases. Of the other two fresh cases, one possessed both t(14; 18) (q32.3;q21.3) and t(8; 14)(q24.1;q32.3)'" and the other had t(8;9)(q24.1;pl3.3).l4 Only one cell line, Karpas 353, exhibited biallelic deletion of CDKN2. These data indicate that CDKN2 is not likely to be the target for 9~1 3 . 3 translocations in leukemias with t(8;9)(q24.l;p13.3).
NHL cell lines. Thirteen NHL, 10 B-NHL, and 3 T-NHL cell lines were examined ( Table  3 , respectively. Lane 3 represents patient no. 14 in Table 3 . Lanes 4 and 5 represent patients no. 15 and 16 in Table 3 Table 3 showing biallelic CDKNZ rearrangement. SKW3, exhibited biallelic CDKNZ deletions. Of these, three represented transformed NHL. Cell line DoHH2 was derived from a patient with immunoblastic transformation of follicular B-NHL.3' Similarly, Granta 452 was derived from a patient with B-cell acute leukemia supravening follicular B-NHL (G.S., M.J.S.D., and E.N., manuscript in preparation). In both these cases it was possible to show that these biallelic deletions had occurred in the original patient material from which the cell line was derived and was therefore not an artifact of prolonged in vitro culture (Fig 3) . High-resolution cytogenetic analysis of cell lines DoHH2 and Karpas 1 1 0 6 failed to detect rearrangement of 9p2 1. Cell line Granta 5 19 was derived from a patient with B-cell acute leukemia supravening mantle cell lymphoma; this cell line expresses the highest level of cyclin Dl in any of the six cell lines with t( 1 I; 14)(q13;q32) examined in our laboratoryz4 and yet also exhibited biallelic CDKNZ deletions. However, this was the only case, of seven with t( 1 1 ; 14)(q13;q32) examined, to exhibit any CDKN2 abnormality.
Fresh cases of NHL. A total of 38 cases of various histologic subtypes of NHL were examined; 7 cases were of T-cell lineage. No deletions were observed in 11 primary follicular B-NHL, 2 mantle cell B-NHL, or 16 cases of primary diffuse large-cell B-NHL. Biallelic rearrangement of CDKNZ with loss of all germline sequence was seen in one case of chemotherapy-resistant monocytoid B-NHL. Also, biallelic CDKNZ deletion was observed in an unusual and rapidly progressive B-NHL in leukemic phase expressing both CD5 and CD10 and exhibiting translocation t(8; 1 l)(q24.l;ql3) with overexpression of cyclin Dl (D.J., D.G.O., and M.J.S.D., unpublished observations).
Of the 7 cases of T-NHL, two of six cases of T-cell lymphoblastic lymphoma exhibited biallelic CDKN2 deletion. One case was of immunoblastic transformation of Sezary syndrome associated with human T-lymphotrophic virus type 1 (HTLV-I) infection in a man of Caribbean origin. CDKNZ was present in a peripheral blood sample taken at diagnosis, but absent from the lymph node of immunoblastic transformation, although analysis of the TCR p gene showed that the same T-cell clone was present in both samples (E. 
DISCUSSION
Deletion of segments of DNA ranging from single basepairs to the megabase deletions visible cytogenetically are a common mechanism of human disease.33 In many hematologic malignancies, recurrent deletions of large chromosomal regions are frequently observed. The association of specific deletions with specific subsets of disease, eg, deletion of 5q in myeloid disorders, 13q in B-CLL, 9p in BCP-ALL, etc. suggests distinct pathologic mechanisms and consequences rather than a random loss of DNA. However, identification of the crucial genes is hampered by the large size of the deletions.
The mapping of the CDKN2 gene to 9p2 1 and the observation of frequent biallelic loss of this gene in a variety of malignant cell lines raised the possibility that CDKN2 is a tumor-suppressor gene, the loss of which is important in the development of several types of malignancy. However, preliminary studies on fresh tumor material suggested that the frequency of biallelic loss of CDKN2 was much lower than that in cell lines and that the high incidence of loss in cell lines represented adaptation to in vitro culture.*' Because abnormalities of both 9p21 and the immediately centromeric chromosomal band 9p13.3 are frequent in both leukemia and lymphoma, we determined the frequency of structural alterations of the CDKN2 gene in a panel of 231 fresh malignancies and 66 lymphoid cell lines, with defined cytogenetic abnormalities, by DNA blot.
We chose this method of analysis because PCR, although adequate for cell lines, can be confounded by contaminating normal cells in patient samples. A number of points emerged from this analysis. Firstly, overall the incidence of structural abnormalities of CDKN2 was low, being observed in 20 of 231 (8.6%) fresh cases and 10 of 66 (17%) cell lines. No CDKN2 deletions or rearrangements were observed in 119 cases of leukemia of mature T or B cells, including 46 cases of T-PLL, a highly aggressive T-cell malignancy associated with a median survival of only 7 months.% Secondly, the absence of CDKN2 abnormalities in EBV-transformed lymphoblastoid cell lines suggests that prolonged in vitro culture does not necessarily lead to CDKN2 abnormalities. Abnormalities of CDKN2 were observed in two distinct subsets of lymphoid malignancy, both in a subset of BCP-ALL and also in some NHL of both T and B lineages. In NHL, CDKNZ abnormalities occurred in high-grade malignancies, including T-cell lymphoblastic NHL, Burkitt's lymphoma, and NHL, that had undergone progression from low-to high-grade disease in vivo. In two cases in which sequential samples were available, biallelic loss of CDKN2 was associated with immunoblastic transformation. In cell lines DoHH2 and Granta 452, which arose from immunoblastic and leukemic transformation of follicular B-NHL, respectively, biallelic deletion of CDKN2 was detected in patient material as well as the cell lines, indicating that deletions were not an artifact of in vitro culture. These data suggest that inactivation of CDKN2 may be a relatively "late" event in NHL, in contrast to other tumors, in which loss of material from 9p is thought to occur "early" in tumor development:
In BCP-ALL, biallelic deletions of CDKNZ were seen in 20% of cases. These cases did not have a common cytoge- netic abnormality and did not appear to be associated with a particularly poor prognosis, although this point requires confirmation from larger studies. Four of the 17 cases analyzed with t(9;22)(q34;ql l ) exhibited biallelic CDKN2 deletions; of these 4, 2 were lymphoid blast crisis of chronic myelogenous leukemia (CML). Whether loss of CDKN2 accompanied the acute transformation could not be determined.
Of the 30 cases with either biallelic deletion or rearrangement of CDKN2, 25 (83%) retained cytogenetically normal copies of chromosome 9p; CDKN2 deletions mostly occurred in the absence of detectable cytogenetic abnormalities of 9p. Only I case of BCP-ALL with interstitial deletion of 9p21-p22 was analyzed (Table 3 , case no. 1 l), and this case exhibited biallelic CDKN2 deletion. However the lack of CDKN2 abnormalities in cases with other abnormalities of 9p13/21, eg, cell line K231 with t(8;9)(q24.l;p13.3) and case no. 15 in Table 3 with t(9; 15)(p2 1 ;q 15). may indicate the presence of other genes in this region of importance in the pathogenesis of lymphoid malignancies.
Seven of the IO cases of BCP-ALL that established overt transplantable leukemia in SCID mice showed biallelic CDKN2 deletions, whereas none of the 1 1 cases that failed to engraft did so. The biologic significance of these observations is not known. Within cytogenetically defined subgroups of BCP-ALL, such as cases with t(4; 1 l)(q21;q23), some cases will grow in SCID mice, whereas others will n~t . . '~"~ The molecular basis for this heterogeneity is not known. Whereas the growth of human tumor cells in SCID mice clearly represents the result of many complex interactions, the data presented here indicate that loss of CDKN2 expression may be an important (although perhaps not essential) parameter in this process. Whether the loss of CDKN2 expression is important for the growth of NHL in SCID mice has not been determined; however, both DoHH2 and Daudi cell lines, grown in SCID mice for the evaluation of novel therapeutic approaches?'..'' exhibit abnormalities of CDKN2.
Finally, rearrangements of CDKN2 were seen in two cases of BCP-ALL, in one Burkitt's cell line (Daudi), and in one For personal use only. on December 27, 2017. by guest www.bloodjournal.org From case of monocytoid B-NHL. Because in all instances they occurred in the absence of cytogenetic change, it is likely that they represent smaller, internal deletions of chromosome 9p21, and might therefore indicate a "hot spot" for recombination in the vicinity of the CDKN2 gene. Molecular cloning of these rearrangements is being undertaken.
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